Semax for ADHD is not supported by a human ADHD trial. As of September 2026, no published study has enrolled people with ADHD and tested whether Semax changes core symptoms or daily functioning. The attention claim comes mainly from a small 1996 experiment in healthy men, while other human studies involved stroke rehabilitation or optic-nerve disease. Those findings can generate questions. They cannot establish Semax as an ADHD treatment.
Is Semax for ADHD supported by human trials?
The direct answer is no. In its May 2026 review of Semax-related bulk drug substances, the FDA noted that Semax had been nominated for ADHD but that the agency did not evaluate that use because it found no supporting literature. The review instead assessed evidence around cerebral ischemia, migraine, and trigeminal neuralgia.
One paper can make the search results look more substantial than they are. A 2007 article in Medical Hypotheses proposed that Semax might have potential in ADHD because preclinical work connected it with dopamine and brain-derived neurotrophic factor, or BDNF (Tsai, 2007). It was a hypothesis paper. It enrolled no participants, administered no Semax, and measured no ADHD outcome.
A useful ADHD trial would need people with a confirmed diagnosis, a comparison group, validated symptom measures, functional outcomes, and systematic safety follow-up. None of that exists for Semax. Difficulty focusing can occur with ADHD, but also with poor sleep, anxiety, depression, medication effects, thyroid disease, and many other conditions. A signal on an attention task does not sort those causes or test the full disorder.
What the Semax research actually studied
The human record is small and mostly Russian. Its populations and endpoints matter more than the word “cognition” in a summary.
| Study | Who was studied | What researchers measured | What it does not show |
|---|---|---|---|
| Kaplan et al., 1996 | 19 healthy adult men | Operator work efficiency and EEG changes; the authors reported an effect lasting 20–24 hours after intranasal administration | No participants had ADHD, and no ADHD symptom scale was used |
| Gusev et al., 2018 | 110 people in rehabilitation after ischemic stroke | Plasma BDNF, motor performance, and Barthel Index function | Stroke recovery is not an attention-disorder model |
| Polunin et al., 2000 | Patients in three groups with several optic-nerve diseases | Visual acuity, visual fields, color vision, and optic-nerve electrophysiology alongside other therapy | Visual outcomes do not test ADHD symptoms |
The Kaplan study is the closest match to the popular idea of Semax for focus. It is still indirect evidence: healthy male volunteers, short experimental exposure, and work-efficiency and EEG endpoints rather than diagnosed ADHD. Its age, size, and lack of modern ADHD measures make it a reason for a proper trial, not a substitute for one.
The stroke and optic-nerve studies are even further away. They asked whether Semax was associated with recovery measures in injured or diseased nervous systems. A finding in those settings cannot be transferred to executive function, impulsivity, hyperactivity, or impairment in a person with ADHD.
Why the BDNF idea is not an ADHD result
BDNF is part of the reason Semax attracts attention. Animal and laboratory work suggests that the peptide can alter BDNF-related signaling, and the 2007 hypothesis article used that observation to propose an ADHD application. The detailed pathway evidence—and its species limits—is covered in how Semax works.
A mechanism is not a clinical outcome. Many compounds change a pathway in cells or animals without producing a meaningful benefit in people. BDNF also participates in broad processes involving neuronal survival and plasticity; changing it does not point specifically to ADHD or predict improvement on an ADHD rating scale. The missing bridge is a controlled human trial in the population being discussed.
This is also why “studied for attention” is the accurate phrase. “Treats ADHD” is not. The first describes a narrow research question. The second would claim a clinical result that researchers have not demonstrated.
Where an off-label conversation can fit
A provider might discuss Semax as an evidence-limited, off-label nootropic studied for aspects of attention. That discussion should begin with what remains unknown: there is no established ADHD response rate, no validated dose for ADHD, no ADHD-specific safety dataset, and no evidence that it improves school, work, relationships, or driving.
Stimulant medications such as methylphenidate and amphetamine remain part of standard ADHD care, supported by clinical guidelines and controlled trials; the American Academy of Pediatrics guideline also places treatment inside an ongoing plan that accounts for age and impairment. Semax does not have comparable evidence and should not be framed as a replacement. Any change to existing ADHD medication belongs with the clinician managing that care.
Semax is not FDA-approved for ADHD or any other U.S. indication; the compounded Semax / Selank formulation offered here is also not FDA-approved. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and clinician.
Promise’s live Semax-containing option is the Semax / Selank blend; standalone Semax is on a waitlist. Evidence about Semax alone does not automatically become evidence about the combination. The Semax versus Selank comparison explains why the two peptides are discussed together without treating them as interchangeable.
What a provider would need to sort out
The first question is the goal: a diagnosed disorder, a new concentration problem, or a general interest in focus. Those are different clinical situations. A provider also needs the current medication list, mental-health and neurological history, sleep pattern, substance use, and whether attention changed suddenly. That context may point toward established ADHD care or toward evaluating another cause before discussing a nootropic.
At Promise, a licensed provider reviews every request, and not everyone qualifies; the provider may prescribe or decline based on medical eligibility. The evidence gap remains part of that decision. A prescription does not turn a hypothesis into an ADHD trial result—it creates an accountable clinical relationship around an individual, evidence-limited choice.